• » Product Advantages
  • Multiplexing
  • Microarray and Miniaturization
  • Automation & Accuracy
• » Application Pipeline
• Autoimmune Application Pipeline
• » Resource Library
• » Technology FAQs

Technology FAQs

1. What's in a test kit?

Everything you will need to conduct an assay for all four Rheumatoid Arthritis markers is contained in a QuantiSpot™ Rheumatoid Arthritis test kit. Specifically it contains a 96 well plate with 73 billable wells (including all controls), positive controls, standards, serum diluents, reporter antibodies and concentrated wash and rinse buffers.

2. What products are SQI Diagnostics launching?

Our lead product, available as an IVD in Canada, is the QuantiSpot(tm) Rheumatoid Arthritis Assay testing for the four predominant biomarkers for Rheumatoid Arthritis. See Application Pipeline.

3. In what markets will we launch?

In Canada began in mid 2009, in U.S. at FDA 510(k) clearance in November 2009 and EU in early 2010.

4. What autoimmune tests will SQI Diagnostics launch?

SQI plans to launch a menu of the high demand autoimmune assays. Please check the applications pipeline page for an update on what is next. Beyond the autoimmune panels, SQI Diagnostics intends to launch multiplexed assays in both the infectious disease and allergen markets.

5. Does SQI require any special equipment?

The SQiDworks Platform is required to use the QuantiSpot Rheumatoid Arthritis Assay.

6. How much does it cost?

A SQI test can potentially reduce your total cost of results by 1/3 compared to the cost of similar competitive assays, please contact SQI for more specific costs. There are many options to acquire the SQiDworks Platform, one of which should be suitable for your laboratory.

7. Are there any special sample preparation requirements for SQI?

No. SQI requires less than one drop of patient serum.

8. How long do results usually take to compile?

In most cases, labs can perform the test and generate results in less than three hours.

9. Do you have FDA clearance?

SQI submitted an FDA 510(k) application in October 2008 and received clearance in November of 2009.